WallStSmart

Precision BioSciences Inc (DTIL)vsVertex Pharmaceuticals Inc (VRTX)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 28654% more annual revenue ($12.95B vs $45.04M). VRTX leads profitability with a 30.7% profit margin vs -85.6%. DTIL trades at a lower P/E of 30.3x. VRTX earns a higher WallStSmart Score of 58/100 (C).

DTIL

Avoid

26

out of 100

Grade: F

Growth: 7.3Profit: 2.0Value: 6.3Quality: 5.5
Piotroski: 2/9Altman Z: -3.79

VRTX

Buy

58

out of 100

Grade: C

Growth: 5.3Profit: 9.0Value: 6.0Quality: 7.5
Piotroski: 3/9Altman Z: 3.61
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DTILUndervalued (+56.6%)

Margin of Safety

+56.6%

Fair Value

$9.38

Current Price

$7.28

$2.10 discount

UndervaluedFair: $9.38Overvalued
VRTXUndervalued (+44.9%)

Margin of Safety

+44.9%

Fair Value

$977.14

Current Price

$537.79

$439.35 discount

UndervaluedFair: $977.14Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DTIL1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
37272.0%10/10

Revenue surging 37272.0% year-over-year

VRTX4 strengths · Avg: 9.8/10
Profit MarginProfitability
30.7%10/10

Keeps 31 of every $100 in revenue as profit

Operating MarginProfitability
37.8%10/10

Strong operational efficiency at 37.8%

Altman Z-ScoreHealth
3.6110/10

Safe zone — low bankruptcy risk

Market CapQuality
$137.57B9/10

Large-cap with strong market position

Areas to Watch

DTIL4 concerns · Avg: 3.5/10
P/E RatioValuation
30.3x4/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$288.76M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

VRTX4 concerns · Avg: 3.3/10
PEG RatioValuation
2.384/10

Expensive relative to growth rate

P/E RatioValuation
34.9x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-39.0%2/10

Earnings declined 39.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : DTIL

The strongest argument for DTIL centers on Revenue Growth. Revenue growth of 37272.0% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 30.7% and operating margin at 37.8%. Revenue growth of 11.8% demonstrates continued momentum.

Bear Case : DTIL

The primary concerns for DTIL are P/E Ratio, EPS Growth, Market Cap.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

DTIL profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

DTIL carries more volatility with a beta of 1.35 — expect wider price swings.

DTIL is growing revenue faster at 37272.0% — sustainability is the question.

VRTX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (58/100 vs 26/100), backed by strong 30.7% margins and 11.8% revenue growth. DTIL offers better value entry with a 56.6% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Precision BioSciences Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States. The company is headquartered in Durham, North Carolina.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?